PMV Pharmaceuticals

PMVPPhase 1

PMV Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, small molecule therapies that selectively target p53 mutations, which are among the most common genetic drivers of cancer. The company's lead program, PC14586, is a first-in-class p53 Y220C reactivator currently in Phase 1/2 clinical trials. PMV's strategy centers on creating tumor-agnostic treatments that address specific p53 mutations, aiming to transform cancer care by targeting a fundamental oncogenic mechanism across multiple tumor types.

Market Cap

$80.0M

Employees

50-100

Focus

Biotech

PMVP · Stock Price

USD 1.5036.01 (-96.00%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for discovering small molecule p53 reactivators that selectively target specific p53 mutations through structural biology, fragment-based screening, and medicinal chemistry optimization.

Pipeline Snapshot

6 drugs in pipeline

Drug	Indication	Stage
PC14586 + Itraconazole	Healthy Volunteers	Phase 1
[14C]-PC14586	Healthy Male Volunteers	Phase 1
Azacitidine + Rezatapopt	Myelodysplastic Syndrome	Phase 1
PC14586 + Rabeprazole + Famotidine	Healthy Volunteers	Phase 1
metformin hydrochloride 500 mg tablet + rosuvastatin 10 mg tablet + repaglinide ...	TP53 Y220C Mutation	Phase 1

Funding History

Total raised: $245M

IPO$150MUndisclosedNov 20, 2020

Series B$70MRA Capital ManagementJun 15, 2018

Series A$25MOrbiMedJun 15, 2015

Opportunities

PMV has the opportunity to establish a new class of tumor-agnostic cancer therapies targeting fundamental p53 mutations.

Success with PC14586 could enable expansion to other p53 hotspot mutations, creating a pipeline of precision oncology drugs.

The growing acceptance of biomarker-driven, tissue-agnostic approvals creates a favorable regulatory pathway.

Risk Factors

The company faces significant clinical development risk as PC14586 is still in early-to-mid stage trials.

The novel mechanism of p53 reactivation remains unproven, and the tumor-agnostic approach may not demonstrate sufficient efficacy across diverse cancers.

PMV also depends on capital markets for funding as a pre-revenue company.

Competitive Landscape

PMV competes in the emerging p53-targeted therapy space against approaches like APR-246 (Aprea Therapeutics), MDM2 inhibitors, and gene therapies. The company's differentiation lies in its mutation-specific, structural biology-driven approach targeting precise p53 pockets, potentially offering greater selectivity than broader p53 reactivators.